Cancer Screening Market in China (2018-2023)

Cancer Screening Market in China (2018-2023)


  • Products Id :- NS361
  • |
  • Pages: 75-90
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

This report will be delivered within 48 working hours of the purchase.

Executive Summary

Cancer screening market in China

China's demand for cancer screening has grown at a fast pace in the past decade. Cancer is one of the most significant healthcare burdens in China. The Chinese economy maintains a high pace of growth stimulated by the consecutive increase in capital investment. The cancer screening market in China is expected to reach USD 1.5 Bn by 2023 at 14 % CAGR.

The cancer screening market in China is classified by end users, screening type and applications. By end users, it is further classified into hospitals, laboratories and independent physicians and clinics. By screening type it is classified into laboratory, genetic, biopsy, imaging and endoscopy testing. By application type, it is further classified into lung, breast, melanoma, kidney and colorectal cancer.

Key growth factors

Rise in the population along with an increase in the patient pool and favourable government policies is a key driver for the market. Also, there is an increase in the aging population, growing levels of pollution and a more sedentary lifestyle.

Threats and key players

Providing drugs at lower prices along with ensuring affordability as well as accessibility will be a major threat for the region. Transparency in medical treatment is being been demanded by people, hence, provision of accurate and proper treatment will be a disguised opportunity.

The key players operating in the valve market are Quest Diagnostics, Hologic Inc., Qiagen, F. Hoffmann-La Roche AG and Abbott Laboratories.

What is covered in the report?

1. Overview of the cancer screening market in China.

2. Market drivers and challenges in the cancer screening market in China.

3. Market trends in the cancer screening market in China.

4. Historical, current and forecasted market size data for segments based on end users (hospitals, Laboratories, and independent physicians and clinics).

5. Historical, current and forecasted market size data for segments based on screening type (Laboratory, genetic, biopsy, imaging and endoscopy testing).

6. Historical, current and forecasted market size data for segmentation based on application (lung, breast, melanoma, kidney and colorectal cancer).

7. Analysis of the competitive landscape and profiles of the major companies operating in the market.

Why buy?

o Understand the demand for cancer screening market in China to determine the viability of the market.

o Identify the developed and emerging markets where cancer screening market in China is sold.

o Identify the challenge areas and address them.

o Develop strategies based on the drivers, trends and highlights for each of the segments.

o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.

o Recognize the key competitors of this market and respond accordingly.

o Knowledge of the initiatives and growth strategies taken up by the major companies and decide on the direction for further growth.

o Define the competitive positioning by comparing the products and services with the key players in the market.

Customizations available

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Chapter 1: Executive summary

1.1 Market scope and segmentation

1.2 Key questions answered in this study

1.3 Executive summary

Chapter 2: Cancer screening market in China-market overview

2.1. China market overview-market trends, market attractiveness analysis, geography-wise market revenue (USD)

2.2. China-market drivers and challenges

2.3. Value chain analysis-industrial valve market in China

2.4. Porter's five forces analysis

Chapter 3. Cancer screening market in China-by end users

3.1. Hospitals-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.2. Laboratories-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

3.3. Independent physicians and clinics-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 4. Cancer screening market in China-by screening type

4.1. Laboratory testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.2. Genetic testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.3. Imaging testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.4. Biopsy testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

4.5. Endoscopy testing-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 5. Cancer screening market in China-by application

5.1. Lung cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.2. Breast cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.3. Melanoma cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.4. Kidney cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

5.5. Colorectal cancer-Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations

Chapter 6: Competitive landscape

6.1. Quest Diagnostics (*)

6.1. a. Company snapshot

6.1. b. Product offerings

6.1. c. Growth strategies

6.1. d. Initiatives

6.1. e. Geographical presence

6.1. f. Key numbers

6.2. Hologic Inc.

6.3. Qiagen

6.4. F. Hoffmann-La Roche AG

6.5. Abbott Laboratories

(*) all the information are similar for the mentioned companies

Chapter 7: Conclusion

Chapter 8: Appendix

8.1. List of tables

8.2. Assumptions

8.3. Research and methodology

8.4. About Netscribes Inc.

Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research. Disclaimer: The report will be delivered within 5-7 business days post payment confirmation

To know more information on Purchase by Section, please send a mail to sales [@] kenresearch.com
 

1. Quest Diagnostics

2. Hologic Inc.

3. Qiagen

4. F. Hoffmann-La Roche AG

5. Abbott Laboratories

select a license
Corporate User License
USD 1950 INR 134550

NEWSLETTER BY CATEGORY




Testimonials

The report was very informative and gives me an interesting view on the Indian market....

We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help...

I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again...

I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ...

The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future...



Ken Research Private Limited, Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

sales [@] kenresearch.com